MEDP vs SNY
Medpace vs Sanofi — AI-powered side-by-side comparison
| Metric | MEDP | SNY |
|---|
| AI Score |
64
|
66
|
| Price |
$596.78
|
$43.73
|
| P/E Ratio |
34.82×
|
22.99×
|
| ROE |
98.3%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
72.8%
|
| Debt / Equity |
0.28×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
72.1
|
53.1
|
| Beta |
1.151
|
0.278
|
| Expected Upside |
+3.0%
|
+3.9%
|
AI Committee View
Current Innellis committee reasoning for MEDP versus SNY.
SNY leads by 2 points.
SNY scores 66/100 (Buy) versus MEDP at 64/100 (Buy).
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 34.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.2 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is price structure making lower highs and lower lows. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 9.6 is inexpensive for the broad market — Value
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.5% pays you to wait — Value
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical